BridgeBio Oncology Therapeutics (BBOT) Long-Term Investments (2024 - 2026)

BridgeBio Oncology Therapeutics has reported Long-Term Investments for 3 years, with the latest figure at $136.6 million in Q1 2026.

• Quarterly Long-Term Investments rose 440699900.0% year-over-year to $136.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $136.6 million (up 440699900.0% YoY) and the FY2024 annual result came in at $634.0, changed N/A from the prior year.
• Long-Term Investments slipped to $136.6 million in Q1 2026 per BBOT's latest filing, from $196.5 million in the prior quarter.
• Over five years, Long-Term Investments peaked at $196.5 million in Q2 2025 and troughed at $6.0 in Q1 2024.
• A 3-year average of $101.6 million and a median of $136.6 million in 2026 frame the typical range for Long-Term Investments.
• The sharpest annual moves came in 2025 and 2026: Long-Term Investments gained 4.72% in 2025, then jumped 440699900.0% in 2026.
• Over 3 years, Long-Term Investments stood at $634.0 in 2024, then soared by 30995729.34% to $196.5 million in 2025, then tumbled by 30.48% to $136.6 million in 2026.
• According to Business Quant data, Long-Term Investments over the past three periods registered $136.6 million, $196.5 million, and $31.0 for Q1 2026, Q2 2025, and Q1 2025 respectively.